Clinical trials: Stage III Non-Small Cell Lung Cancer AJCC v7
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion
- Trial name
- NCT00126581
- Testing
- Carboplatin, Erlotinib, Erlotinib Hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Non-small-cell Lung Cancer
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher…
- Trial name
- 358 (NCT03589547)
- Testing
- Durvalumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Lung Cancer
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293332
- Testing
- bevacizumab, carboplatin, docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Non-small Cell Lung Cancer Stage III
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well.
- Trial name
- NCT02053285
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Carcinoma, Non-Small-Cell Lung
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins…
- Trial name
- NCT01909752
- Testing
- Cyclophosphamide, DRibble vaccine, Imiquimod
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UbiVac
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trametinib when given together with combination chemotherapy and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01912625
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Image Guided Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01993810
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- Radiation Therapy Oncology Group
Non Small Cell Lung Carcinoma
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or…
- Trial name
- NCT00234468
- Testing
- Iressa (Gefitinib)
- Where
- 32 sites in Italy
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Non Small-cell Lung Cancer
Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer
Randomized study in 2 arms, without any masking in patients with non small cell lung cancer, histologically or cytologically confirmed, not liable to surgery, stage IIIB or IIIA, according to the TNM classification of the…
- Trial name
- GECP0008 (NCT01652820)
- Testing
- Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day, Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d
- Volunteers
- 140 people
- Sponsor
- Spanish Lung Cancer Group
Lung Cancer
Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer
RATIONALE: Imaging procedures, such as positron emission tomography (PET) scan and CT scan, may help doctors plan radiation therapy for patients with non-small cell lung cancer.
- Trial name
- NCT00310219
- Testing
- computed tomography, positron emission tomography
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
- Trial name
- NCT03840902
- Testing
- M7824, Durvalumab, Etoposide
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 153 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small-cell Lung Cancer Patients
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
This is a randomized, non-comparative, phase II study investigating whether: 1) the addition of durvalumab to investigator's choice second line chemotherapy prolongs survival versus investigator's choice second line chemotherapy…
- Trial name
- NCT05568212
- Testing
- Durvalumab, Olaparib tablet, Single-agent chemotherapy
- Where
- Italy
- Volunteers
- 176 people
- Sponsor
- Fondazione Ricerca Traslazionale
Esophageal, Toxicity
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis during concurrent paclitaxel and carboplatin…
- Trial name
- MnSOD (NCT00618917)
- Testing
- Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Joel Greenberger
Non-Small-Cell-Lung Cancer
Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC
The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is possible to obtain optimal efficacy with minimal…
- Trial name
- CHER@NOS (NCT00463515)
- Testing
- carboplatin/gemcitabine, cisplatin/radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 77 people
- Sponsor
- University Hospital, Antwerp
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as irinotecan, cisplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616785
- Testing
- cisplatin, etoposide, irinotecan hydrochloride
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Yonsei University
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003235
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 294 people
- Sponsor
- Eastern Cooperative Oncology Group
Stage III Non-small Cell Lung Cancer
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
This is a pilot phase II study of histology based consolidation chemotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer (NSCLC) following concurrent chemo-radiotherapy.
- Trial name
- NCT01336543
- Testing
- Chemotherapy following concurrent Chemoradiotherapy
- Where
- United States
- Sponsor
- Syed Jafri
Lung Cancer
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00124618
- Testing
- cetuximab, radiation therapy
- Where
- 175 sites in United States
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology